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Abstract: New resolving bases for ibuprofen 1 and mandelic acid 2 were studied and 
qualified by their binary phase diagrams of the corresponding salts. It was shown that 
analysis of the binary phase diagrams gives a good prediction for a resolution process. A 
comparison of resolving bases revealed that (S)-phenylglycinol (S)-7 is the best resolving 
base for ibuprofen 1. By the same procedure, various resolving bases for mandelic acid 
2 were studied. The known resolving base (S)-MBA 9 was found to be the best for this 
acid. © 1997 Elsevier Science Ltd. All rights reserved. 
I n t roduct ion  
Resolution of enantiomers is an important method for the industrial production of enantiopure 
compounds. The most frequently applied method is formation and selective crystallization of 
diastereomeric salts. The major problem of this approach is identifying a suitable resolving agent. 
Until now, no suitable method is available to predict a resolving agent for a given racemate. 1 The 
conditions required for an efficient resolution are: the diastereomeric salts consist of a mechanical 
mixture of crystals of the pure diastereomers (eutectic mixture); both salt pairs can be crystallized 
separately and have substantial differences in physico-chemical properties, especially solubilities. 2 
Optimum conditions (e.g. concentration, temperature) for a resolution process can be quantified 
by construction of the ternary (solubility) phase diagram. However, this requires a large amount of 
experimental data. It is a well known fact that binary (melting) phase diagrams are often a good 
approximation for ternary diagrams especially for selection and qualification of a resolving agent for 
a given substrate. 3,4 Thus, the efficiency of a resolution depends on the location of the eutectic. The 
formation or existence of a eutectic mixture, a primary condition for a resolution, can be determined. 
Moreover, the diagram allows calculation of the maximum yield (Rmax) and efficiency 5 (S). Starting 
from the racemic composition (x0.5) and going to the isolation of a pure diastereomer, the following 
equations can be used to calculate these parameters: 6 
0.5 - Xeu 
Rma~ = - -  X 100% (Rm~x = 0 - 50%) (1) 
1 - Xeu 
1 - 2Xeu 
S=kt= ~ (S=0-1)  (2) 
1 - Xeu 
where x is the molar fraction of the less soluble diastereomer, Xeu the eutectic composition, k the 
chemical yield (k=2 for 100%) and t the optical purity (t=-I for 100% ee). A more successful resolution 
is expected when the diagram has a steeper slope, i.e. a larger difference between the melting points 
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Figure 1. Substrates and resolving bases. 
~ 9  NH2 
of the pure diastereomers and a more eccentric eutectic. The binary phase diagram of a diastereomeric 
mixture can be constructed using the Schr6der-van Laar equation. 4 
The use of binary phase diagrams for qualification and selection of resolving agents also has some 
limitations, i.e. diagrams cannot be constructed when thermal decomposition takes place, the role of 
solvates cannot be observed and both diastereomers are not always available. 
Using this approach, five new resolving bases for ibuprofen 1 have been tested, (S)-1-(benzyloxy- 
methyl)propylamine (BOP) (S)-3, (-)-ephedrine (-)-4a, (4S,5R)-(+)-l,2,5,5-2,2,3,4-tetramethyl- 
5-phenyl-l,3-oxazolidine (TPO) (+)-5, (R)-l-phenyl-2-p-tolylethylamine (PTEA) (R)-6 and (S)- 
phenyiglycinol (S)-7. Also two new resolving bases for mandelic acid 2 were tried, (-)-N- 
methylephedrine (-) -4b and (+)-(2S,3R)-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol (DMDB) 
(+)-8 (Figure 1). 
Binary phase diagrams of these ibuprofenates and mandelates were constructed using differential 
scanning calorimetry (DSC). Experimental data are compared with calculated iagrams using the 
Schr6der-van Laar equation. The diagrams were then used for the qualification of resolving bases 
for the given substrate. Known resolving agents with well-described physico-chemical data are also 
included. 
Results and discussion 
Ibuprofen 
According to known methods, ibuprofen 1 can be resolved using either et-methylbenzylamine 
(MBA) 7 9 or lysine, s The binary phase diagram of the ibuprofen.MBA salt 10 has not been reported 
previously. Therefore, this diagram was constructed revealing a eutectic mixture (Figure 2A). Several 
of the salt mixtures used to construct this diagram were analyzed by NMR and subjected to elemental 
analysis. There were no indications for the occurrence of solvates. Both the eutectic point (Xeu=0.66) 
and the fiat slope are rather unfavorable for a good resolution process. The calculated maximum yield 
of enantiopure (S)-9 is limited to 24% starting from the racemic omposition. Resolution according 
to a patent of Ethyl 7a confirmed the expected limitations. 
Lysine is an interesting resolving base because ibuprofen 1can be marketed as lysinate salt 11. The 
phase diagram of this lysinate 11 could not be constructed as no clear melting behavior of these salts 
was observed uring the DSC experiments. From NMR, DSC and elemental nalysis it was concluded 
that a solvate of salt 11 was formed with 0.5 equiv, of water. Resolution experiments 8 indicated an 
efficiency (Sexp) of 0.5---0.6. 
The binary phase diagram of ibuprofen-(S)-BOP salt 12 is shown in Figure 2B. The conglomerate 
has an unfavorable eutectic point (xe,=0.33) which results in a low maximum yield and efficiency 
of 25% and 0.5 respectively. Moreover, the small difference between the melting points of the pure 
diastereomers results in a fiat slope and will make a resolution process difficult, which was confirmed 
by some attempted resolution experiments. Several other 2-amino- 1-butanols were investigated but all 
formed oily ibuprofenates. 
7] 
© 
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Figure 2. Binary phase diagrams of ibuprofen. 
I -  I10  
With (-)-ephedrine ( - ) -4a  as a resolving agent the formation of crystalline salt with ibuprofen 1 
was achieved. However, this ibuprofenate 13 was not suitable for the resolution of ibuprofen because 
it exists as a solid solution (Figure 2C) as was deduced from thermograms which showed a single 
broad peak. A few resolution experiments using (-)-ephedrine ( - ) -4  in various solvents (e.g. toluene, 
diisopropyl ether) confirmed the formation of a solid solution as only low des and low yields could be 
obtained. Several substituted ephedrines were also studied, however all of them failed to crystallize. 
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Table 1. Resolving agents for ibuprofen 1 and their resolving abilities a 
Salt Type AHe~p ~-Ie~c T~p Tc.~c Tcu xcu Rmx Sc.~c 
(kJ/mole) (kJ/mole)(*C) (°C) (°C) (%) 
(S,S)-I0 conglomerate 59.8 61.8 178 178 149 0.66 24 0.48 
(R,S)-I0 52.9 58.8 159 159 149 
lysinate 11 solvate 0.5-0.68 
(S,S)-12 conglomerate 30.0 29.7 80 79 66 0.33 25 0.51 
(R,S)-12 37.4 42.6 93 93 
(S,(-))-13 solid solution 38.5 94 
(R,(-))-I3 41.5 121 
(S,R)-14 partial solid solution / 53.5 167 
conglomerate 
(R,R)-14 50.9 160 
(S,S) -15 conglomerate 44.4 44.2 152 152 97 0.83 40 0.80 
(R,S)-I5 20.1 ! 8.5 104 108 
Al'~x p is the experimental heat of fusion, Tc~ the experimental melting point, AFLa~ and Tc.,c are the calculated values by 
the SchrOder-van Laar equation (5-3), T~ and x~ were determined using the calculated phase diagram, the maximum 
yield (R~)  and efficiency (S) were calculated using equations 5-1, 5-2 and x~. 
Oxazolidine (+)-5 derived from (-)-ephedrine did produce crystalline salts with ibuprofen 1, but these 
salts decomposed during resolution experiments even at room temperature. 
Several substituted MBAs t were studied as potential resolving agents. Only (R)-PTEA (R)-6 gave 
a crystalline ibuprofenate 14. Constructing the phase diagram of ibuprofenate 14 results in a relatively 
rare diagram (Figure 2D). Diastereomeric salt mixtures 14 were analyzed by NMR and elemental 
analysis showing salts in a 1:1 ratio without the inclusion of solvent. Consequently, this diagram is 
best typified as a solid solution between crystalline diastereomeric salts existing as conglomerates. 9 
The diagram does not represent a complete solid solution because no broad single peaks were 
observed. Most thermograms showed two overlapping peaks, which could be separated using peak- 
fitting calculations l° in some cases. The possibility of the formation of a (1:1) double salt was rejected 
due to the absence of the typical maximum at x=-0.5) ~ The use of PTEA 6 as a resolving agent for 
ibuprofen 1 was abandoned because of the above behavior of this ibuprofenate. 
Finally, (S)-phenylglycinol (S)-7 was studied as a possible resolving agent for ibuprofen 1. The 
melting diagram (Figure 2E) of the ibuprofenate salt 15 indicated the formation of a diastereomeric 
mixture with a favorable utectic omposition, moreover the diagram has a steep slope. The calculated 
diagram based on the pure diastereomers is in full agreement with the experimental results. Hence, 
phenylglycinol 7 can be qualified as a potentially suitable resolving base for ibuprofen 1. Based on the 
eutectic point (Xeu=0.83) a resolution with a maximum yield of 40% and efficiency of 0.8 is possible. 
Resolution experiments of ibuprofen 1 with (S)-phenylglycinol (S)-7 in acetone or toluene/hexane 
mixtures resulted in the isolation of (S,S)-15 as crystalline salt with des up to 53%, yields above 50% 
and efficiencies of about 0.5. Several other substituted phenylglycinols were synthesized but all of 
them formed oily ibuprofenates. 
The results of the various resolving bases investigated for ibuprofen 1 are summarized in 
Table 1 showing phenylglycinol 7 as the most promising resolving agent for ibuprofen 1. Currently, 
phenylglycinol 7 is further developed as a resolving base for ibuprofen 1. 
Mandelic acid 
Mandelic acid 2 is a widely applied resolving agent for various amines) 2 Both antipodes 
are commercially available at low prices in enantiopure form) 3 Physico-chemically well-studied 
t Enantiopure substituted MBAs N-(p-hydroxybenzyl)-l-(R)-p-tolyl-ethylamine, l-(R)-phenyl-2-p-tolylethylamine (R)-6 and 
N-(p-methoxy-o-hydroxyhenzyl)-l-(R)-p-tolyl-ethylamine were kind gifts from Sumitomo Chemical Company, Ltd, Japan. 
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Figure 3. Binary phase diagrams of mandelates. 
mandelate salts used for resolution purposes are MBA mandelate 16 (Figure 3A), 14 2-benzylamino- 
1-butanol mandelate 17, 3J5 (R)-2-tert-butyl-3-methylimidazolidin-4-one (BMI) mandelate 18 3'16 and 
(+)-cinchonine mandelate 19.17 Other known resolving agents are brucine, 18 quinine, la quinidine, 18 
(-)-ephedrine, ]9 (-)-2-amino-l-butanol, 2° amphetamine lac and adrenaline) 4c 
Two new resolving bases (-)-N-methylephedrine ( - ) -4b and (+)-DMDB (+)-8, formed crystalline 
mandelates 20 and 21 respectively. Their resolving ability was studied by their binary phase diagrams 
which showed the formation of eutectic mixtures (Figure 3B and 3C). The physico-chemical properties 
of these mixtures are summarized in Table 2 and were compared with known mandelates 16-19. The 
experimental results of mandelates 20 and 21 are in good agreement with the calculated diagrams. 
However, two deviations were observed when comparing the experimental and calculated heats of 
fusion of (S,(-))-20 and (R,(+))-21. In both cases a difference of about 15 kJ/mol was observed. 
This may imply that the simplified Schr&ler-van Laar equation is not valid for these sections of the 
diagrams. This deviation may be attributed to several effects, e.g. the specific heat capacities of the 
pure diastereomers cannot be neglected, the mixtures of diastereomers do not show ideal behavior in 
the solid or liquid phase, polymorphism or incongruent melting. 21 
The results in Table 2 clearly reveal MBA 9 as the most appropriate resolving base for mandelic acid 
2 (Figure 3A). The eutectic composition of the corresponding mandelate salt 16 lies toward the end of 
the diagram resulting in an almost ideal efficiency and yield. Moreover, the large difference between 
the melting points of the pure salts results in a steep slope of the diagram. Also, both enantiomers of 
MBA 9 are readily available at the same price allowing straightforward preparation of either enantiomer 
of mandelic acid 2. Only when the primary amine MBA 9 is not preferred (for example because of 
amide formation) tertiary amines (-)-N-methylephedrine ( - ) -4b and BMI 18 are good alternatives. 
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Table 2. Resolving agents for mandelic acid 2 and their resolving abilities a
Salt Type AI-I m, Al-l~c T~ T~c T~ x~ ~ S~¢ S~p 
00/mole) (kJ/mole) (*C) (*C) (°C) (%) 
(S,S)-16 "3 conglomerate 48.9 177 106 108 0.09 45 0.9 
(R,S)-16 30.3 109 
(p)-17 '3 conglomerate 32.1 108 69 0.32 26 0.45 
(n)-17 28.8 84 
(R,R)-I8 '3 conglomerate 51.5 118 76 0.15 41 0.82 
(S,R)-18 30.6 79 
19 solvate 0.3-0.5 
(S,(-))-20 conglomerate 30.0 13.5 91 90 75 0.18 39 0.78 
(R,(-))-20 40.9 36.9 132 129 
(S,(+))-21 conglomerate 59.2 60.0 169 168 142 0.65 23 0.46 
(R,(+))-21 55.9 40.0 158 158 
0.86 
0.32 
0.82 
a) Al-le~ is the experimental heat of fusion. T,~ the experimental melting point and S~ the experimental 
efficiency, AH,~ and T..~ are the calculated values by the Schr6der-van Lanr equation, T.. and x~ were 
determined by using the calculated phase diagram, the maximum yield (P.~) and efficiency (S..,c) were 
calculated by equations 5-1, 5-2 and x~. 
Experimental 
tH-NMR spectra were recorded on a Bruker AC-100 (100 MHz, FT) spectrometer with tetra- 
methylsilane as internal standard. IR spectra were recorded on a Perkin-Elmer 298 spectrophotometer 
or Perkin-Elmer FTIR 1720-X spectrophotometer. Elemental analyses were performed with a Carlo 
Erba CHNSO 1108 elemental analyzer. For mass spectroscopy, a double focusing VG 7070E was 
used. For the chemical ionization (CI) technique, methane was used as the reacting gas. Melting 
points were measured on a Reichert Thermopan microscope (uncorrected) oron a Perkin-Elmer DSC7 
instrument. Optical rotations were determined on a Perkin-Elmer 241 polarimeter at589 nm, equipped 
with a quartz cell of 1.00 dm path length. The polarimeter was connected with a thermostat for exact 
temperature control. For column chromatography, the 'flash technique '22 was used with silica gel 60H 
(Merck) as the stationary phase and a pressure of about 1.5 bar. Tetrahydrofuran was distilled from 
lithium aluminum hydride. All other solvents and reagents were either p.a. or 'reinst' quality and used 
as obtained from the supplier. 
Racemic and enantiopure (S)-ibuprofen was a gift from DSM Andeno, Venlo, The Netherlands. (R)- 
ibuprofen was prepared by purification of diastereomerically enriched (R)-ibuprofen-(R)-MBA salt 7a 
or (R)-ibuprofen sodium salt} 3 The chiral bases N-fp-hydroxybenzyl)-l-(R)-p-tolyl-ethylamine, l- 
(R)-phenyl-2-p-tolyl-ethylamine and N-(p-methoxy-o-hydroxybenzyl)-1-(R)-p-tolyl-ethylamine were 
a gift from Sumitomo Chemical Co. Ltd, Japan. 
Enantiomeric excesses of ibuprofen and mandelic acid were determined using chiral HPLC 
(performed on a Spectra Physics HPLC system equipped with a chiral Daicel Chiralcel 
ODH column, 25×0.46 cm, particle size: 5 lam, ambient temperature): ibuprofen (eluent: 
hexane:2-propanol:trifluoroacetic ac d=980:20:2.5, v/v), mandelic acid (eluent: hexane:2- 
propanol:trifluoroacetic acid=875:125:2.5, v/v). 
DSC thermograms were determined using a Perkin-Elmer DSC7 instrument, calibrated with In and 
Zn or Sn. Samples (2-10 mg) were weighed with an accuracy of 0.01 mg and encapsulated in stainless 
steel large volume pans (75 lal). Thermograms were recorded at a scanning rate of 10°C/min, a data 
rate of 0.4-0.8 sec/point and with an empty pan as reference under a nitrogen atmosphere. Melting 
points are given as the top of the peaks because of broad peaks. If necessary, deconvolution of peaks 
was performed using PeakFit~ version 4 for Win32 (Jandel Scientific Software). Pearson IV peaks 
were used as the peak description. Solid solution diagrams were constructed using the beginning and 
maximum of the broad peaks for the solidus and liquidus curves, respectively. The start emperature for 
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melting mixtures of diastereomers was corrected with the width of the peaks of the pure diastereomers 
(Tmax-Ts,art). 
Preparation of salts 
Pure diastereomeric salts were prepared by mixing equimolar amounts of enantiopure base and acid 
1 or 2 in ethanol. The salts obtained were allowed to crystallize, filtered and dried in vacuo. 
Diastereomeric salt mixtures were prepared as described by Jacques, Collet and Wilen. 24 Accurately 
weighed amounts of the pure salts were dissolved in ethanol and the solution obtained was concentrated 
and dried in vacuo. The composition of mixtures obtained were analyzed by chiral HPLC on liberated 
ibuprofen 1 or mandelic acid 2. 
Hydrolysis of ibuprofen and mandelic acid salts (general procedure) 
Ibuprofenates were hydrolyzed with 1 N aqueous ulfuric acid at pH I-2, stirred for 0.5 h at room 
temperature and extracted with dichloromethane (three times). The combined organic layers were 
extracted with brine, dried over MgSO4 and concentrated in vacuo to give ibuprofen 1. 
Mandelates were hydrolyzed with 2 N aqueous hydrochloric acid at pH 1-2, stirred for 0.5 h at 
room temperature and extracted with ethyl acetate (three times). The combined organic layers were 
extracted with brine, dried over MgSO4 and concentrated in vacuo to give mandelic acid 2. 
( S )- l-( Benzyloxymethyl )propylamine (S)-3 
Amine (S)-3 was prepared using the Williamson reaction. 25 To a slurry of sodium hydride (6.6 g, 
120 mmol) in dry tetrahydrofuran (50 ml) under a nitrogen atmosphere, (S)-2-amino-1-butanol (10.0 
g, 110 mmol) was gradually added. The mixture was stirred for 17 h at 80°C and then a solution of 
benzylchloride (15.6 g, 250 mmol) in dry tetrahydrofuran (100 ml) was added ropwise. The resulting 
solution was stirred for 20 h at 70°C and subsequently cooled to room temperature. Ethyl acetate (100 
ml), methanol (100 ml) and water (100 ml) were added and the resulting solution was concentrated 
to a volume of about 100 ml. Water (200 ml) was added, the mixture was acidified to pH 1-2 and 
extracted twice with dichloromethane. The water layer was treated with sodium hydrogen carbonate 
until pH 11-12 and extracted with dichloromethane (three times). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to give pure (S)-3 as an oil (15.2 g, 77%). [or]t) 25 -18.1 
(methanol, c=l.0). IR (CC14, cm-l): V 3400-2800 (NH), 1100 (C-O). IH-NMR (CDCI3, ppm): 6 
0.85 (t, 3H, CH3CH2, J=7.0 Hz), 1.0---1.8 (m, 4H, CH2CH3, NH2) 2.8-3.0 (m, IH, CH), 3.1-3.5 (m, 
2H, OCH2CH), 4.52 (s, 2H, OCH2Ar), 7.1-7.4 (m, 5H, ArH). Literature: 26 [0t]D 25 --15.7 and -18.9 
(ethanol, c= 1.5), IR and 1H-NMR were identical with those described above. 
( 4S,5R)-2,2,3,4- Tetramethyl-5-phenyl-oxazolidine (+)-(4S,5R)-5 
A solution of (-)-ephedrine 4a (24 g, 140 mmol) and p-toluenesulfonic a id (2.5 g, 14 mmol) 
in a mixture of chloroform (100 ml) and 2,2-dimethoxypropane (90 ml, 700 mmol) was refluxed 
for one week. The mixture was then cooled to room temperature, concentrated and dissolved in 
dichloromethane (100 ml). This solution was extracted twice with 1 N aqueous odium hydroxide 
and concentrated in vacuo. The product was purified by column chromatography (fash, silica gel 
60H, dichloromethane:methanol:Et3N=600:100:2, v/v) to give pure (+)-(4S,5R)-5 (4.4 g, 15%). Mp 
40--42°C, [Ot]D 25 +17.7 (ethanol, c=l.0). Literature: 27 Mp 39--43°C, [0t]D 25 +22.0 (ethanol). Calculated 
for CI3HI9NO: 76.06% C, 9.33% H, 6.82% N; found: 75.76% C, 9.19% H, 6.88% N. IH-NMR 
(CDCI3, ppm): 8 0.63 (d, 3H, CH3CH, J=6.4 Hz), 1.21 (s, 3H, CH3C), 1.52 (s, 3H, CH3C), 2.26 (s, 
3H, CH3N), 3.14 (dq, 1H, CHN, J=6.4, 8.0 Hz), 5.03 (d, 1H, CHO, J=8.0 Hz), 7.2-7.4 (m, 5H, ArH). 
MS (El): m/e (%) 206 (M÷+I, 18), 190 (M*-Me, 33), 148 (206-acetone, 100), 133 (148-Me, 6). 
Ibuprofen . (S )-ot-methylbenzylamine salt 10 
(S,S)-10: Mp 178.0°C, [et]D 25 +0.89 (ethanol, c=l.0). Calculated for C21H29NO2: 77.03% C, 8.93% 
H, 4.28% N; found: 76.77% C, 8.84% H, 4.37% N. 'H-NMR (CDCI3, ppm): 8 0.87 (d, 6H, (CH3)2CH, 
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J=6.5 Hz), 1.32 and 1.35 (2d, 6H, CH3CHN and CH3CHCO, J=6.9 Hz), 1.6-1.9 (m, 1H, CHCH2), 
2.41 (d, 2H, CH2, J=7.1 Hz), 3.48 (q, 1H, CHCO, J=7.0 Hz), 4.00 (q, 1H, CHN, J=6.9 Hz), 5.96 (s, 
3H, NH3+), 7.0-7.4 (m, 9H, ArH,). IR (KBr, cm-1): v 3100-2500, 2220 (NH), 1625, 1545 (C=O). 
(R,S)-10: Mp 158.6°C, [tX]o 25 -40.0 (ethanol, c=0.1). Calculated for C21H29NO2: 77.03% C, 8.93% 
H, 4.28% N; found: 77.07% C, 8.76% H, 4.39% N. 1H-NMR (CDCI3, ppm): 8 0.83 (d, 6H, (CH3)zCH, 
J=6.4 Hz), 1.32 and 1.38 (2d, 6H, CH3CHCO and CH3CHN, J=6.9 Hz), 1.6-1.9 (m, 1H, CHCH2), 
2.38 (d, 2H, CH2, J=7.1 Hz), 3.55 (q, 1H, CHCO, J=6.9 Hz), 4.02 (q, 1H, CHN, J=6.9 Hz), 5.04 (s, 
3H, NH3+), 7.0-7.4 (m, 9H, ArH,). IR (KBr, cm-I): v 3100-2300, 2200 (NH), 1630, 1550 (C=O). 
Resolution of ibuprofen ! by ( S )-c¢-methylbenzylamine( S )-9 
Ibuprofen 1 was resolved following a procedure of Ethyl. 7a Racemic ibuprofen (RS)-I (1.03 g, 
5.0 mmol) and triethylamine (0.7 ml, 5.0 mmol) were dissolved in octane (1 ml) under a nitrogen 
atmosphere. The stirred mixture was heated to 125°C and to the clear solution obtained, (S)-MBA 
(S)-9 (0.32 ml, 2.5 mmol) was added dropwise. The white heterogeneous mixture was stirred for 3 h 
at 125°C and slowly cooled to room temperature. The precipitate was filtered off, washed with octane, 
dried in vacuo and weighed. A fraction of the salt was hydrolyzed and the ee of liberated ibuprofen 
1 was analyzed by chiral HPLC. The principal part of the obtained salt was recrystallized twice from 
2-propanol to give pure (S)-ibuprofen.(S)-MBA (S,S)-10 as white crystals (0.6 g, 1.95 mmol) in 78% 
yield and with a de of 80.6%. The 1H-NMR was in full accordance with 10. The aforementioned 
patent claims the isolation of optically pure salt 10 in 69% yield after three crystallizations. 
(S)-Lysine ibuprofenate 11 
The salts were prepared according to the general procedure using a mixture of water:ethanol=95:5 
(v/v) as the solvent. 
(S,S)-ll: Calculated for CI9H32N204.0.5 H20: 63.13% C, 9.20% H, 7.75% N; found: 63.20% C, 
9.06% H, 7.63% N. IH-NMR (D20, ppm): ~i 0.84 (d, 6H, (CH3)2CH, J=6.6 Hz), 1.2-2.0 (m, 10H, 
(CH2)3, CH3CH, CH(CH3)2), 2.45 (d, 2H, CH2Ar, J=6.9 Hz), 2.97 (t, 2H, CH2N, J=7.2 Hz), 3.4-3.8 
(m, 2H, CHN, CHAr), 7.0-7.4 (m, 4H, ArH). 
(RS,S)-ll: Calculated for CI9H32N204.0.5 H20: 63.13% C, 9.20% H, 7.75% N; found: 63.34% C, 
8.84% H, 7.73% N. IH-NMR (D20, ppm): 8 0.85 (d, 6H, (CH3)2CH, J=6.6 Hz), 1.2-2.0 (m, 10H, 
(CH2)3, CH3CH, CH(CH3)2), 2.45 (d, 2H, CH2Ar, J=7.1 Hz), 2.99 (t, 2H, CH2N, J=7.6 Hz), 3.4-3.8 
(m, 2H, CHN, CHAr), 7.0-7.4 (m, 4H, ArH). 
( S )- l-Benzyloxymethyl )propylamine ibuprof enate 12 
(S,S)-12: Calculated for C24H35NO3: 74.77% C, 9.15% H, 3.63% N; found: 74.58% C, 9.17% H, 
3.58% N. IR (KBr, cm-I): v 3100-2500, 2190 (NH), 1640, 1550, 1520 (C--O), 1100 (C-O). IH- 
NMR (CDCI3, ppm): • 0.7-1.0 (m, 9H, (CH3)2CH, CH3CH2), 1.2-1.6 (m, 5H, CH2CH3, CH3CHCO) 
1.6-2.0 (m, 1H, CH(CH3)2), 2.40 (d, 2H, CH2CH(CH3)2, J=7.0 Hz) 2.8-3.1 (m, IH, CHN), 3.1-3.7 
(m, 3H, CHCO, OCH2CH), 4.46 (s, 2H, OCHzAr), 5.43 (S, 3H, NH3+), 6.9-7.5 (m, 9H, ArH). 
(RS,S)-12: Calculated for C24H35NO3: 74.77% C, 9.15% H, 3.63% N; found: 74.55% C, 9.16% H, 
3.60% N. IR (KBr, cm-l): v 3100-2200, 2100 (NH), 1630, 1550, 1530 (C---O). tH-NMR (CDCI3, 
ppm): fi 0.7-1.0 (m, 9H, (CH3)2CH, CH3CH2), 1.2-1.5 (m, 5H, CH2CH3, CH3CHCO) 1.6-1.9 (m, 
1H, CH(CH3)2), 2.40 (d, 2H, CH2CH(CH3)2, J=7.0 Hz) 2.8-3.0 (m, 1H, CHN), 3.1-3.7 (m, 3H, 
CHCO, OCH2CH), 4.46 (s, 2H, OCH2Ar), 5.84 (S, 3H, NH3+), 6.9-7.5 (m, 9H, ArH). 
(-)-Ephedrine ibuprofenate 13 
(S,(-))-13: Calculated for C23H34NO3: 74.16% C, 9.20% H, 3.76% N; found: 74.56% C, 9.06% 
H, 3.86% N. IR (KBr, cm-I): v 3500-2000 (OH, NH), 1580-1560 (C=O). IH-NMR (CDC13, ppm): 
~i 0.83 (d, 6H, (CH3)2CH, J=6.4 Hz), 0.86 (d, 3H, CH3CHN, J=6.6 Hz), 1.41 (d, 3H, CHaCHCO, 
J=7.1 Hz), 1.5-1.9 (m, 1H, CHCH2), 2.28 (s, 3H, CH3N), 2.37 (d, 2H, CH2, J=7.1 Hz), 2.76 (dq, 1H, 
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CHN, J=6.6, 1.7 Hz), 3.55 (q, 1H, CHCO, J=7.1 Hz), 5.06 (d, 1H, CHOH, J=l.7 Hz)), 6.9-7.4 (m, 
9H, ArH), 7.6 (s, 3H, NH2 ÷, OH). 
(RS,(-))-13: Calculated for C23H34NO3: 74.16% C, 9.20% H, 3.76% N; found: 74.08% C, 8.89% 
H, 3.76% N. IR (KBr, cm-~): v 3500-2100 (OH, NH), 2490 (NH), 1560 (C=O). IH-NMR (CDCI3, 
ppm): 6 0.83 (d, 6H, (CH3)2CH, J=6.4 Hz), 0.86 (d, 3H, CH3CHN, J=6.6 Hz), 1.39 (d, 3H, CH3CHCO, 
J=7.1 Hz), 1.5-1.9 (m, 1H, CHCH2), 2.24 (s, 3H, CH3N), 2.35 (d, 2H, CH2, J=7.1 Hz), 2.76 (dq, IH, 
CHN, J=6.6, 1.7 Hz), 3.52 (q, 1H, CHCO, J=7.1 Hz), 5.07 (d, 1H, CHOH, J=l.7 Hz)), 6.9-7.4 (m, 
9H, ArH), 8.2(s, 3H, NH2 +, OH). 
(R)-l-Phenyl-2-p-tolylethylamine ibuprofenate 14 
(S,R)-14: [0t]o 25 +70.9 (ethanol, c=l.0). Calculated for C28H35NO2: 80.54% C, 8.45% H, 3.35% N; 
found: 80.30% C, 8.41% H, 3.42% N. IR (KBr, cm-l): v 3200-2300 (NH), 1625 (C=O). IH-NMR 
(CDCi3, ppm): ~i 0.89 (d, 6H, (CH3)2CH, J=6.0 Hz), 1.47 (d, 3H, CH3CHCO, J=7.1 Hz), 1.6-2.0 
(m, 1H, CH(CH3)2), 2.31 (s, 3H, CH3Ar), 2.44 (d, 2H, CH2CH(CH3)2, J=7.0 Hz), 2.8-3.0 (m, 2H, 
CH2CHN), 3.65 (q, 1H, CHCO, J=7.1 Hz), 4.14 (dd, 1H, CHN, J=7.8, 8.0 Hz), 5.16 (s, 3H, NH3+), 
7.0-7.4 (m, 13H, ArH,). 
(R,R)-14: [0riD 25 +27.3 (ethanol, c=0.3). Calculated for C2sH35NO2: 80.54% C, 8.45% H, 3.35% N; 
found: 79.83% C, 8.29% H, 3.51% N. IR (KBr, cm-t): v 3200-2300, 2200-2100 (NH), 1615 (C=O). 
IH-NMR (CDCI3, ppm): ~ 0.88 (d, 6H, (CH3)2CH, J=6.5 Hz), 1.43 (d, 3H, CH3CHCO, J=7.1 Hz), 
1.6-2.0 (m, 1H, CH(CH3)2), 2.30 (s, 3H, CH3Ar), 2.42 (d, 2H, CH2CH(CH3)2, J=7.1 Hz), 2.8-3.0 
(m, 2H, CH2CHN), 3.60 (q, 1H, CHCO, J=7.2 Hz), 4.12 (dd, 1H, CHN, J=7.8, 7.8 Hz), 5.17 (s, 3H, 
NH3+), 6.9-7.4 (m, 13H, ArH,). 
(RS,R)-14: Calculated for C2sH35NO2: 80.54% C, 8.45% H, 3.35% N; found: 80.61% C, 8.41% 
H, 3.42% N. IR (KBr, cm-I): v 3200-2300, 220(02100 (NH), 1620 (C=O). IH-NMR was identical 
to (S,R)- and (R,R)-lg. 
(S)-Phenylglycinol ibuprofenate 15 
(S,S)-15: Calculated for C21H29NO3: 73.44% C, 8.51% H, 4.08% N; found: 73.29% C, 8.50% 
H, 4.25% N. IR (KBr, cm-l): v 3500-2200, 2180 (OH, NH), 1640, 1550-1520 (C=O). IH-NMR 
(CDCI3, ppm): ~i 0.88 (d, 6H, (CH3)2CH, J=6.7 Hz), 1.45 (d, 3H, CH3CHCO, J=7.1 Hz), 1.6-2.0 (m, 
1H, CHCH2), 2.42 (d, 2H, CH2Ar, J=7.1 Hz), 3.4-3.8 (m, 3H, CH2OH, CHCO), 4.10 (dd, 1H, CHN, 
J=8.5, 4.3 Hz), 4.76 (s, 4H, OH, NH3+), 6.9-7.5 (m, 9H, ArH). 
(RS,S)-15: Calculated for C21H29NO3: 73.44% C, 8.51% H, 4.08% N; found: 72.85% C, 8.37% 
H, 4.06% N. IR (KBr, cm-~): v 350(02200, 2160 (OH, NH), 1660, 1550 (C=O). IH-NMR (CDCI3, 
ppm): ~ 0.89 (d, 6H, (CH3)2CH, J=6.5 Hz), 1.46 (d, 3H, CH3CHCO, J=7.2 Hz), 1.6-2.0 (m, 1H, 
CHCH2), 2.43 (d, 2H, CH2Ar, J=7.0 Hz), 3.5-3.8 (m, 3H, CH2OH, CHCO), 4.11 (dd, 1H, CHN, 
J=8.5, 4.2 Hz), 4.76 (s, 4H, OH, NH3+), 6.9-7.5 (m, 9H, ArH). 
Resolution of ibuprofen I by (S)-phenylglycinol (S)-7 
Racemic ibuprofen (RS)-I (0.5 g, 2.4 mmol) and (S)-phenylglycinol (S)-7 (0.33 g, 2.4 mmol) were 
dissolved in hot acetone (5 ml) or a hot mixture of toluene:hexane=2:1 (v/v) and gradually cooled. The 
formed crystalline salt (S,S)-15 was filtered off, washed with cold solvent, dried in vacuo and weighed. 
A fraction of the salt was hydrolyzed and the ee of liberated ibuprofen 1 was analyzed by chiral 
HPLC. Results: acetone as solvent: 0.52 g (1.5 mmol, 63%), 39.4% de, S=0.50; toluene:hexane=2:l 
(v/v) as solvent: 0.60 g (1.8 mmol, 73%), 37% de, S=0.54. 
(-  )-N-Methylephedrine mandelate 20 
(S,(-))-20: [0t]D 25 +24.6 (ethanol, c=l.0). Calculated for CI9H25NO4: 68.86% C, 7.60% H, 4.23% 
N; found: 68.59% C, 7.55% H, 4.26% N. IR (KBr, cm-I): v 3500--3000 (OH), 3000-2100 (NH), 
1600 (C=O). lH-NMR (CDCI3, ppm): fi 1.00 (d, 3H, CH3CH, J=6.9 Hz), 2.67 (s, 6H, N(CH3)2), 
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3.14 (dq, IH, CHCH3, J=2.1, 6.9 Hz), 4.97 (s, 1H, CHCO), 5.41 (d, 1H, CHO, J=2.1 Hz)), 7.0-7.5 
(m, 13H, ArH, NH ÷, 2OH). 
(R,(-))-20: [0t]D 25 +65.8 (ethanol, c=l.0). Calculated for C19H25NO4: 68.86% C, 7.60% H, 4.23% 
N; found: 68.67% C, 7.61% H, 4.25% N. IR (KBr, cm-l): v 3500 (OH), 3400-2200 (NH), 1600 
(C--O). tH-NMR (CDCI3, ppm): 6 1.00 (d, 3H, CH3CH, J=7.1 Hz), 2.70 (s, 6H, N(CH3)2), 3.12 (dq, 
1H, CHCH3, J=2.0, 7.1 Hz), 4.94 (s, 1H, CHCO), 5.36 (d, 1H, CHO, J=2.1 Hz), 7.0-7.5 (m, 13H, 
ArH, NH +, 2OH). 
(RS,(-))-20: Calculated for C19H25NO4: 68.86% C, 7.60% H, 4.23% N; found: 68.49% C, 7.58% 
H, 4.26% N. IR (KBr, cm-l): v 3500-3000 (OH), 3000-2100 (NH), 1600 (C=O). IH-NMR (CDCI3, 
ppm): ~i 1.00 (d, 3H, CH3CH, J=6.7 Hz), 2.69 (s, 6H, N(CH3)2), 3.13 (dq, 1H, CHCH3, J=2.0, 6.7 
Hz), 4.96 (s, 1H, CHCO), 5.39 (d, 1H, CHO, J=2.0 Hz), 7.0-7.5 (m, 13H, ArH, NH +, 2OH). 
( + )-( 2S,3 R )-4-Dimethylamino- 3-methyl- ,2-diphenyl- 2 butanol mande late 21 
(S,(+))-21: [0t]D 25 +47.8 (ethanol, c=l.0). Calculated for C27H33NO4: 74.76% C, 7.64% H, 3.22% 
N; found: 74.36% C, 7.58% H, 3.23% N. FTIR (KBr, cm-l): v 3500-3000, 3401, 3162 (OH), 
30(0)-2000, 2640, 2400 (NH), 1617 (C--O). IH-NMR (CDC13, ppm): ~i 0.96 (d, 3H, CH3CH, J=6.7 
Hz), 1.9-2.8 (m, 3H, CHCH3, CH2Ar), 2.40 (s, 6H, N(CH3)2), 3.0-3.4 (m, 2H, CH2N), 4.96 (s, 1H, 
CHO), 7.0-7.6 (m, 15H, ArH), 8.06 (s, 3H, NH +, 2OH). 
(R,(+))-21: [¢X]D 25 --28.9 (ethanol, c=l.0). Calculated for C27H33NO4: 74.76% C, 7.64% H, 3.22% 
N; found: 74.36% C, 7.59% H, 3.23% N. FTIR (KBr, cm-I): v 3500-3000, 3372, 3244 (OH), 
3000-2000 (NH), 1623 (C--O). IH-NMR (CDCI3, ppm): ~i 0.95 (d, 3H, CH3CH, J=6.5 Hz), 1.9-2.9 
(m, 3H, CHCH3, CH2Ar), 2.40 (s, 6H, N(CH3)2), 3.0-3.4 (m, 2H, CH2N), 4.96 (s, 1H, CHO), 6.28 
(s, 3H, NH ÷, 2OH), 7.0-7.6 (m, 15H, ArH). 
(RS,(+))-21: Calculated for C27H33NO4: 74.76% C, 7.64% H, 3.22% N; found: 74.36% C, 7.58% 
H, 3.23% N. FTIR (KBr, cm-l): v 3500-3000, 3372, 3164 (OH), 3000-2100 (NH), 1617 (C=O). 
IH-NMR (CDCI3, ppm): 8 0.97 (d, 3H, CH3CH, J=6.5 Hz), 1.9-2.9 (m, 3H, CHCH3, CH2Ar), 2.41 
(s, 6H, N(CH3)2), 3.0-3.4 (m, 2H, CH2N), 4.96 (s, 1H, CHO), 6.65 (s, 3H, NH +, 2OH), 7.1-7.5 (m, 
15H, ArH). 
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